Navigo Proteins GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Scil Proteins GmbH (to 2017)
3
Ending by 2030
Dec 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 14, 2027The maintenance fee for Targeted Compounds for the Site-Specific Coupling of Chemical Moieties Comprising a Peptide Linker (US 11,813,336) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Novel Binding Proteins Based on Di-Ubiquitin Muteins and Methods for Generation (US 10,584,152) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,748,351 | Method for Identifying Hetero-Multimeric Modified Ubiquitin Proteins with Binding Capability to Ligands In force · High confidence | In force | High confidence | |
| US 8,921,304 | Modified Ubiquitin Proteins Having a Specific Binding Activity for the Extradomain B of Fibronectin In force · High confidence | In force | High confidence | |
| US 9,492,572 | Dimeric Binding Proteins Based on Modified Ubiquitins In force · High confidence | In force | High confidence | |
| US 10,584,152 | Novel Binding Proteins Based on Di-Ubiquitin Muteins and Methods for Generation In force · High confidence | In force | High confidence | |
| US 10,858,405 | Novel Egfr Binding Proteins In force · High confidence | In force | High confidence | |
| US 10,808,042 | Immunoglobulin-binding proteins and their use in affinity purification In force · From the USPTO record | In force | From the USPTO record | |
| US 11,230,576 | Novel Alkaline Stable Immunoglobulin-Binding Proteins In force · High confidence | In force | High confidence | |
| US 11,813,336 | Targeted Compounds for the Site-Specific Coupling of Chemical Moieties Comprising a Peptide Linker In force · High confidence | In force | High confidence | |
| US 11,414,466 | Fusion Proteins with Specificity for Ed-B and Long Serum Half-Life for Diagnosis or Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 12,509,493 | Novel FOLR1 Specific Binding Proteins for Cancer Diagnosis and Treatment In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 3 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 1 abandoned · 4 no status recorded